[ad_1]
As part of its Rusal volunteer vaccination program, in collaboration with the Russian Federation, the two (2) thousandth patient received his dose of GamEvak Combi vaccine yesterday, Tuesday 27 November 2018, reports Special Envoy of Guineematin.com in Kindia.
These vaccinations are carried out on the site of the Center for Research in Epidemiology-Microbiology and Medical Care (CREMS), built by Rusal in the region of Kindia. The company Rusal, which is one of the country's largest bauxite producers, had invested more than $ 10 million in this center when Guinea was affected by the Ebola outbreak in 2015.
Miss Victorine Koïvogui, a student from her state, completed the list of two thousand (2,000) people who received their dose of GamEvak Combi vaccine against the Ebola virus. As a reward, Miss Victorine received a motorcycle offered by the company Rusal. An official ceremony was organized for this purpose at the CREMS with the presence of the Director General of the National Agency for Health Security (ANSS), Dr. Sakoba Kéïta, the Governor of the Administrative Region of Kindia, Hadja Sarangbé Camara, the Ambbadador of the Russian Federation to Guinea, His Excellency Alexandre Bregadzé, Director General of Rusal-Guinea, Pavel Vbadiliev, and Secretaries General of the Ministries of Livestock and Higher Education and Scientific Research.
In her remarks, Dr Alya Latyr Sylla, CREMS Administrator General, explained that the vaccine was developed through collaboration between Russian and Guinean researchers. And, it was later that he was sent to Guinea to resume research in the context of obtaining approval by the WHO. "The vaccine gave effective results, every two thousand volunteers who received the vaccine dose showed no side effects; therefore, their health is not threatened, "said Dr. Sylla.
On behalf of the people of Kindia, the governor, Hadja Sarangbé Camara, thanked the Russian Federation and the Rusal Company for their continued support in maintaining the health of the people of Kindia. She later recalled the efforts of the Russian-Rusal duo alongside Guinea since the appearance of the Ebola virus disease through the endowment of a mobile laboratory and the creation of CREMS.
Placing the event in context, Rusal CEO Pavel Vasliev expressed confidence that this program has made a significant contribution to the health of the Guinean nation. "We are very pleased that the Rusal company has been able to make its necessary contribution from the material and financial point of view for the success of the project," he said, thanking Russian scientists and doctors who have agreed to come a year at CREMS to coordinate the program, but also the Guinean authorities and the populations of Kindia for their collaboration.
While welcoming the cooperation relations between the Russian Federation and the Republic of Guinea, His Excellency Alexandre BREGADZE, appreciated the great contribution of the company Rusal to the implementation of the project. "The Rusal company built the CREMS in the shortest possible time during the Ebola outbreak. A company that remains today one of the main technical and financial partners of Guinea, "said the Russian ambbadador, among others.
On behalf of the Minister of Health, the Director General of the National Health Security Agency (ANSS), Dr. Sakoba Kéïta also expressed his appreciation to the Russian Federation for its many efforts in the process of development of Guinea, particularly in the area of health. Among these actions, Dr. Sakoba Kéîta cited the training of executives, the promotion to research and the provision of a high-level laboratory (B3) and a center for the management of infectious diseases, not to mention the supply of inputs and drugs, etc.
Regarding the ceremony yesterday, the DG of ANSS considers that it is an important step in consolidating the efforts of the Russian Federation in search of an effective vaccine against Ebola virus disease. "We believe that this hope generated by the discovery of this vaccine will allow the whole of humanity to have an effective weapon for the control of the future outbreaks of the Ebola virus disease", he hopes, before rebaduring the Guinean population that already, teams of health interventions are being put in place to face any eventuality.
Remember that the vaccine "GamEvak Combi" was made by the Federal Center for Research in Epidemiology and Microbiology N.F. Gamaleya. The drug was developed on the order of the President of the Russian Federation Vladimir Putin who was asked in late 2014 by the President of the Republic of Guinea, Alpha Condé. The vaccine was created via a biotechnological method without using the pathogenic Ebola virus. The vaccine base consists of genetic material containing an adenovirus and vesicular stomatitis virus safe for humans and in which a gene containing information on the structure of the glycoprotein of Ebola virus has been introduced. Preclinical and clinical tests on the vaccine have confirmed that it is safe and more effective at boosting immunity than those manufactured elsewhere. In addition, one of the main advantages of the Russian vaccine is its ease of preservation: the drug "GamEvak Combi" can be transported at a temperature of -16 degrees Celsius, while those manufactured elsewhere require the maintenance of temperature less than -60 C, which is difficult to implement in African climatic conditions.
The vaccination and follow-up examination of Guinean residents takes place at the Center for Research in Epidemiology-Microbiology and Medical Care (CREMS), built by the company RUSAL during the Ebola outbreak. We learn that this center has no equivalent in West Africa in the use of high technologies and biosecurity systems. The center was created taking into account all the recommendations of international humanitarian organizations and is equipped with modern medical and laboratory equipment. RUSAL's investments in the construction of CREMS amount to more than $ 10 million. During the Ebola outbreak, the center posted the best figures for healing in Guinea: 62.5% of CREMS patients with a confirmed diagnosis of Ebola were treated successfully. Currently, CREMS is the main center for the study and prevention of infectious diseases in Guinea, as well as the training center for epidemiologists in the country.
Ousmane Cissé for Aminata.com
Source link
